Table 9 (A) Quality of life of non-metastatic gastric cancer patients, (B) Median difference before–after of quality of Life
| Â | Mean (before) | Std. deviation | Std. error mean | P-value | Mean (after) | Std. deviation | Std. deviation | P-value |
|---|---|---|---|---|---|---|---|---|
(A) Quality of life in patients with non-metastatic gastric cancer | ||||||||
Global quality (BCc1 nanomedicine) | 40.75 | 9.013 | 1.840 | 0.118 | 38.46 | 9.532 | 9.013 | 0.200 |
Global quality (Placebo) | 47.11 | 12.009 | 2.831 | 0.200 | 50.11 | 14.046 | 12.009 | 0.200 |
| Â | Mean* | Std. deviation | Std. error mean | P-value |
|---|---|---|---|---|
(B) Median difference (before–after) of quality of life | ||||
Quality of BCc1 (before–after) | 2.29 | 5.497 | 1.122 | 0.053 |
Quality of Placebo (before–after) | − 3 | 12.009 | 2.831 | 0.038 |